Ocugen expands global patent portfolio for OCU200

Ocugen, Inc., a biopharmaceutical company developing treatments for sight-threatening diseases announced the Company continues to expand its global patent protection for OCU200, its product candidate to treat wet age-related macular degeneration and other neovascular diseases of the eye.  Together with patents already issued by the United States Patent and Trademark Office (USPTO) and the Japan Patent Office (JPO), Ocugen recently received Notification of Intent to Grant Patent from the European Patent Office (EPO) thereby strengthening the Company’s patent position within major markets. These patents and Notification of Intent to Grant cover compositions of matter and methods of use for OCU200 – a fusion protein that combines the anti-angiogenic properties of tumstatin with the targeting properties of transferrin.